Peptide-based cancer vaccines are attractive as they can elicit antigen-specific cytotoxic T lymphocytes (CTLs) with minimal side effects. However, low immunogenic responses have delayed their translation to the clinic. Adjuvants, which are required in vaccine... ...

请注册登录后继续浏览